Sana Biotechnology, Inc. — Director's Dealing 2021

Sep 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sana Biotechnology, Inc. (SANA)
CIK: 0001770121
Period of Report: 2021-09-02

Reporting Person: Hordo Christian (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-02	Common Stock	M	6558.00	$1.48	Acquired	977356.00	Direct
2021-09-02	Common Stock	S	6558.00	$25.0019	Disposed	970798.00	Direct
2021-09-02	Common Stock	S	1400.00	$25.0039	Disposed	969398.00	Direct
2021-09-03	Common Stock	M	700.00	$1.48	Acquired	970098.00	Direct
2021-09-03	Common Stock	S	700.00	$25.00	Disposed	969398.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-02	Stock Option (Right to Buy)	$1.48	M	6558.00	Disposed	2030-01-26	Common Stock (6558.00)	Direct
2021-09-03	Stock Option (Right to Buy)	$1.48	M	700.00	Disposed	2030-01-26	Common Stock (700.00)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.015, inclusive.

F4: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter.